Global PD-L1 Biomarker Testing Market Insights and Forecast to 2028

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
Market Analysis and Insights: Global PD-L1 Biomarker Testing Market
The global PD-L1 Biomarker Testing market size is projected to reach US$ 14870 million by 2028, from US$ 1470.5 million in 2021, at a CAGR of 38.7% during 2022-2028.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global PD-L1 Biomarker Testing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global PD-L1 Biomarker Testing market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global PD-L1 Biomarker Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global PD-L1 Biomarker Testing market.
Global PD-L1 Biomarker Testing Scope and Market Size
PD-L1 Biomarker Testing market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global PD-L1 Biomarker Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segment by Application
Hospital
Diagnostic Center
Others
By Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA